La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The Role of Glial Reaction and Inflammation in Parkinson's Disease

Identifieur interne : 003101 ( Main/Exploration ); précédent : 003100; suivant : 003102

The Role of Glial Reaction and Inflammation in Parkinson's Disease

Auteurs : E. C. Hirsch [France] ; T. Breidert [France] ; E. Rousselet [France] ; S. Hunot [France] ; A. Hartmann [France] ; P. P. Michel [France]

Source :

RBID : ISTEX:7EC790141B211503BA4D587100832AD9E681C8B0

English descriptors

Abstract

Abstract: The glial reaction is generally considered to be a consequence of neuronal death in neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease. In Parkinson's disease, postmortem examination reveals a loss of dopaminergic neurons in the substantia nigra associated with a massive astrogliosis and the presence of activated microglial cells. Recent evidence suggests that the disease may progress even when the initial cause of neuronal degeneration has disappeared, suggesting that toxic substances released by the glial cells may be involved in the propagation and perpetuation of neuronal degeneration. Glial cells can release deleterious compounds such as proinflammatory cytokines (TNF‐α, Il‐1β, IFN‐γ), which may act by stimulating nitric oxide production in glial cells, or which may exert a more direct deleterious effect on dopaminergic neurons by activating receptors that contain intracytoplasmic death domains involved in apoptosis. In line with this possibility, an activation of proteases such as caspase‐3 and caspase‐8, which are known effectors of apoptosis, has been reported in Parkinson's disease. Yet, caspase inhibitors or invalidation of TNF‐α receptors does not protect dopaminergic neurons against degeneration in experimental models of the disease, suggesting that manipulation of a single signaling pathway may not be sufficient to protect dopaminergic neurons. In contrast, the antiinflammatory drugs pioglitazone, a PPAR‐γ agonist, and the tetracycline derivative minocycline have been shown to reduce glial activation and protect the substantia nigra in an animal model of the disease. Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinson's disease.

Url:
DOI: 10.1111/j.1749-6632.2003.tb07478.x


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The Role of Glial Reaction and Inflammation in Parkinson's Disease</title>
<author>
<name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
</author>
<author>
<name sortKey="Breidert, T" sort="Breidert, T" uniqKey="Breidert T" first="T." last="Breidert">T. Breidert</name>
</author>
<author>
<name sortKey="Rousselet, E" sort="Rousselet, E" uniqKey="Rousselet E" first="E." last="Rousselet">E. Rousselet</name>
</author>
<author>
<name sortKey="Hunot, S" sort="Hunot, S" uniqKey="Hunot S" first="S." last="Hunot">S. Hunot</name>
</author>
<author>
<name sortKey="Hartmann, A" sort="Hartmann, A" uniqKey="Hartmann A" first="A." last="Hartmann">A. Hartmann</name>
</author>
<author>
<name sortKey="Michel, P P" sort="Michel, P P" uniqKey="Michel P" first="P. P." last="Michel">P. P. Michel</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7EC790141B211503BA4D587100832AD9E681C8B0</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1111/j.1749-6632.2003.tb07478.x</idno>
<idno type="url">https://api.istex.fr/document/7EC790141B211503BA4D587100832AD9E681C8B0/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F05</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F05</idno>
<idno type="wicri:Area/Istex/Curation">001F03</idno>
<idno type="wicri:Area/Istex/Checkpoint">000C56</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C56</idno>
<idno type="wicri:doubleKey">0077-8923:2003:Hirsch E:the:role:of</idno>
<idno type="wicri:Area/Main/Merge">003575</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12846989</idno>
<idno type="wicri:Area/PubMed/Corpus">001099</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001099</idno>
<idno type="wicri:Area/PubMed/Curation">001058</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001058</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001058</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001058</idno>
<idno type="wicri:Area/Ncbi/Merge">000345</idno>
<idno type="wicri:Area/Ncbi/Curation">000345</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000345</idno>
<idno type="wicri:doubleKey">0077-8923:2003:Hirsch E:the:role:of</idno>
<idno type="wicri:Area/Main/Merge">003496</idno>
<idno type="wicri:Area/Main/Curation">003101</idno>
<idno type="wicri:Area/Main/Exploration">003101</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">The Role of Glial Reaction and Inflammation in Parkinson's Disease</title>
<author>
<name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">France</country>
</affiliation>
</author>
<author>
<name sortKey="Breidert, T" sort="Breidert, T" uniqKey="Breidert T" first="T." last="Breidert">T. Breidert</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Rousselet, E" sort="Rousselet, E" uniqKey="Rousselet E" first="E." last="Rousselet">E. Rousselet</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hunot, S" sort="Hunot, S" uniqKey="Hunot S" first="S." last="Hunot">S. Hunot</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hartmann, A" sort="Hartmann, A" uniqKey="Hartmann A" first="A." last="Hartmann">A. Hartmann</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Michel, P P" sort="Michel, P P" uniqKey="Michel P" first="P. P." last="Michel">P. P. Michel</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Annals of the New York Academy of Sciences</title>
<idno type="ISSN">0077-8923</idno>
<idno type="eISSN">1749-6632</idno>
<imprint>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2003-06">2003-06</date>
<biblScope unit="volume">991</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="214">214</biblScope>
<biblScope unit="page" to="228">228</biblScope>
</imprint>
<idno type="ISSN">0077-8923</idno>
</series>
<idno type="istex">7EC790141B211503BA4D587100832AD9E681C8B0</idno>
<idno type="DOI">10.1111/j.1749-6632.2003.tb07478.x</idno>
<idno type="ArticleID">NYAS214</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0077-8923</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Anti-Inflammatory Agents (therapeutic use)</term>
<term>Cytokines (metabolism)</term>
<term>Dopamine (metabolism)</term>
<term>Humans</term>
<term>Inflammation (etiology)</term>
<term>Nerve Degeneration (physiopathology)</term>
<term>Neuroglia</term>
<term>Neurons (metabolism)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (pathology)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>apoptosis</term>
<term>cytokines</term>
<term>dopamine neuron</term>
<term>neuroprotection</term>
<term>substantia nigra</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Cytokines</term>
<term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Anti-Inflammatory Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Neurons</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Humans</term>
<term>Neuroglia</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Abstract: The glial reaction is generally considered to be a consequence of neuronal death in neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease. In Parkinson's disease, postmortem examination reveals a loss of dopaminergic neurons in the substantia nigra associated with a massive astrogliosis and the presence of activated microglial cells. Recent evidence suggests that the disease may progress even when the initial cause of neuronal degeneration has disappeared, suggesting that toxic substances released by the glial cells may be involved in the propagation and perpetuation of neuronal degeneration. Glial cells can release deleterious compounds such as proinflammatory cytokines (TNF‐α, Il‐1β, IFN‐γ), which may act by stimulating nitric oxide production in glial cells, or which may exert a more direct deleterious effect on dopaminergic neurons by activating receptors that contain intracytoplasmic death domains involved in apoptosis. In line with this possibility, an activation of proteases such as caspase‐3 and caspase‐8, which are known effectors of apoptosis, has been reported in Parkinson's disease. Yet, caspase inhibitors or invalidation of TNF‐α receptors does not protect dopaminergic neurons against degeneration in experimental models of the disease, suggesting that manipulation of a single signaling pathway may not be sufficient to protect dopaminergic neurons. In contrast, the antiinflammatory drugs pioglitazone, a PPAR‐γ agonist, and the tetracycline derivative minocycline have been shown to reduce glial activation and protect the substantia nigra in an animal model of the disease. Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinson's disease.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>Île-de-France</li>
</region>
<settlement>
<li>Paris</li>
</settlement>
</list>
<tree>
<country name="France">
<region name="Île-de-France">
<name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
</region>
<name sortKey="Breidert, T" sort="Breidert, T" uniqKey="Breidert T" first="T." last="Breidert">T. Breidert</name>
<name sortKey="Hartmann, A" sort="Hartmann, A" uniqKey="Hartmann A" first="A." last="Hartmann">A. Hartmann</name>
<name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<name sortKey="Hunot, S" sort="Hunot, S" uniqKey="Hunot S" first="S." last="Hunot">S. Hunot</name>
<name sortKey="Michel, P P" sort="Michel, P P" uniqKey="Michel P" first="P. P." last="Michel">P. P. Michel</name>
<name sortKey="Rousselet, E" sort="Rousselet, E" uniqKey="Rousselet E" first="E." last="Rousselet">E. Rousselet</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003101 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003101 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:7EC790141B211503BA4D587100832AD9E681C8B0
   |texte=   The Role of Glial Reaction and Inflammation in Parkinson's Disease
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024